Invictus Therapeutics develops next-generation insulin analogs for people with insulin-dependent diabetes, with a lead candidate engineered to be ultra-rapid, concentrated, and stable at room temperature for up to a year. The company also maintains a pipeline of ultra-stable insulins and miniaturized pump technology intended to support evolving insulin delivery systems and improve patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current insulin formulations are not optimally suited for next-generation insulin pumps, which require ultra-rapid action, higher concentration, and stability at room temperature to function effectively and improve patient quality of life. Existing options often fall short in one or more of these areas, creating persistent unmet medical needs for insulin-dependent diabetic patients.
Solution
Invictus Therapeutics is developing a portfolio of novel insulin analogs designed to address the shortcomings of current therapies. Their lead candidate is an ultra-rapid, concentrated, room-temperature-stable insulin analog produced from a stable monomeric formulation that can be up to 10 times more concentrated than standard insulin. This formulation is engineered to remain stable at 30°C for at least a year, addressing major usability and storage challenges for insulin pump users. The company is also advancing additional ultra-stable insulin assets and miniaturized pump technology, all aimed at improving therapy delivery and outcomes for the growing population of insulin-dependent diabetics.
Target Audience
Primary stakeholders are insulin pump manufacturers and diabetes care providers seeking advanced insulin formulations for improved patient management, as well as the broader population of insulin-dependent diabetic patients who may benefit from next-generation delivery systems.
Features
- Lead candidate offers best-in-class pharmacokinetic properties for rapid glucose control
- Stable monomeric formulation supports concentrations up to 10 times standard insulin
- Formulation remains stable at room temperature (30°C/86°F) for at least one year, reducing cold-chain dependency
- Pipeline includes additional ultra-stable insulin analogs for broader therapeutic applications
- Development of miniaturized pump technology designed to pair with ultra-rapid insulins for enhanced delivery precision